DelMar Pharmaceuticals is focused on the development and commercialization of proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The company’s lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. For more information, visit the company’s website at www.del-marpharma.com